0000000000741985

AUTHOR

E. Castagnola

showing 3 related works from this author

Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

2017

lcsh:Diseases of the musculoskeletal systemlcsh:RJ1-570lcsh:Pediatricslcsh:RC925-935Meeting Abstracts
researchProduct

Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020

2020

Data on features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children and adolescents are scarce. We report preliminary results of an Italian multicentre study comprising 168 laboratory-confirmed paediatric cases (median: 2.3 years, range: 1 day–17.7 years, 55.9% males), of which 67.9% were hospitalised and 19.6% had comorbidities. Fever was the most common symptom, gastrointestinal manifestations were frequent; two children required intensive care, five had seizures, 49 received experimental treatments and all recovered.

MalePediatricsEpidemiologyProtease InhibitorComorbiditymedicine.disease_causeClinical Laboratory TechniqueSevere Acute Respiratory SyndromeDisease OutbreaksFeces0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaCOVID-19 TestingRetrospective StudiePandemic030212 general & internal medicineViralChildCoronavirusPediatricDisease OutbreakCoinfectionHospitals PediatricSettore MED/38HospitalsDiarrheaTreatment OutcomeSARS-CoV-2 infection; children; covid-19; hydroxychloroquine; pneumonia; Adolescent; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Testing; Child; Child Preschool; Chronic Disease; Clinical Laboratory Techniques; Coinfection; Comorbidity; Coronavirus; Coronavirus Infections; Diarrhea; Disease Outbreaks; Feces; Female; Fever; Hospitals Pediatric; Humans; Immunocompromised Host; Infant; Infant Newborn; Italy; Male; Noninvasive Ventilation; Pandemics; Pneumonia Viral; Protease Inhibitors; Retrospective Studies; SARS-CoV-2; Severe Acute Respiratory Syndrome; Treatment OutcomeItalyChild PreschoolCoinfectionFemalemedicine.symptomCoronavirus InfectionsRapid CommunicationHumanDiarrheamedicine.medical_specialtyCOVID-19; ItalyhydroxychloroquineAdolescentFeverCoronaviruPneumonia ViralAntiviral Agents03 medical and health sciencesBetacoronavirusImmunocompromised Hostchildren030225 pediatricsVirologyIntensive caremedicineHumanspneumoniaProtease InhibitorsPreschoolPandemicsRetrospective StudiesAntiviral Agentchildren; covid-19; hydroxychloroquine; pneumonia; SARS-CoV-2 infection; Adolescent; Antiviral Agents; Betacoronavirus; Child; Child Preschool; Chronic Disease; Clinical Laboratory Techniques; Coinfection; Comorbidity; Coronavirus; Coronavirus Infections; Diarrhea; Disease Outbreaks; Feces; Female; Fever; Hospitals Pediatric; Humans; Immunocompromised Host; Infant; Infant Newborn; Italy; Male; Noninvasive Ventilation; Pandemics; Pneumonia Viral; Protease Inhibitors; Retrospective Studies; Severe Acute Respiratory Syndrome; Treatment OutcomeNoninvasive VentilationBetacoronaviruPandemicbusiness.industryClinical Laboratory TechniquesCoronavirus InfectionSARS-CoV-2pneumonia.SARS-CoV-2 infectionPublic Health Environmental and Occupational HealthInfant NewbornCOVID-19InfantRetrospective cohort studymedicine.diseaseNewbornComorbidityCoronavirusPneumoniaChronic DiseaseFecebusiness
researchProduct

TREATMENT OF VISCERAL LEISHMANIASIS IN CHILDREN USING LIPOSOMAL AMPHOTHERICIN B

1997

We used liposomal amphotericin B as first-choice treatment of visceral leishmaniasis in 106 immunocompetent children who acquired the infection in a temperate region of southern Europe (Italy) where Leishmania infantum visceral leishmaniasis is endemic. The aim of the study was to identify the minimum total dose of liposomal amphotericin B needed to cure the infection in children and reduce the period of hospitalization. We conclude that the optimal regimen in immunocompetent children with L. infantum visceral leishmaniasis to be a total dose of 18 mg/kg of liposomal amphotericin B (3 mg/kg per day for 5 days, followed by 3 mg/kg administered as an outpatient regimen on day 10).

leishmaniasis
researchProduct